Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Receivables: 2015-2024

Historic Receivables for Cartesian Therapeutics (RNAC) over the last 9 years, with Dec 2024 value amounting to $872,000.

  • Cartesian Therapeutics' Receivables fell 87.57% to $722,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 million, marking a year-over-year decrease of 93.19%. This contributed to the annual value of $872,000 for FY2024, which is 90.15% down from last year.
  • According to the latest figures from FY2024, Cartesian Therapeutics' Receivables is $872,000, which was down 90.15% from $8.9 million recorded in FY2023.
  • In the past 5 years, Cartesian Therapeutics' Receivables ranged from a high of $9.9 million in FY2021 and a low of $872,000 during FY2024.
  • Its 3-year average for Receivables is $6.5 million, with a median of $8.9 million in 2023.
  • Per our database at Business Quant, Cartesian Therapeutics' Receivables spiked by 72.48% in 2020 and then slumped by 90.15% in 2024.
  • Yearly analysis of 5 years shows Cartesian Therapeutics' Receivables stood at $8.6 million in 2020, then increased by 14.96% to $9.9 million in 2021, then decreased by 1.57% to $9.8 million in 2022, then dropped by 9.29% to $8.9 million in 2023, then plummeted by 90.15% to $872,000 in 2024.